Customized treatment for very premature babies with heart duct issue
Part of Heart & circulation clinical trials.
This trial tests a personalized approach for treating a heart duct problem (PDA) in very premature babies (born before 32 weeks). It uses special markers and drug delivery systems to find the best treatment for each baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be born before 32 weeks of pregnancy.
- You (parent or guardian) must be able to talk with the study team and sign a consent form.
- Your baby cannot have severe heart defects other than PDA, such as certain types of tetralogy of Fallot or coarctation of the aorta.
- Your baby cannot have major birth defects, chromosome problems, or serious brain issues.
- Your baby cannot have severe infection, bleeding problems, or organ failure.
- Your baby cannot have had other treatments for PDA before joining this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving medicine soon can help preterm babies with a patent ductus arteriosus (a temporary leaking blood vessel in the heart). It aims to see if early treatment improves outcomes for very early gestational age infants.
This trial compares an early procedure to close a heart vessel called the ductus arteriosus versus careful observation alone in very low-birth-weight preterm infants. It aims to see whether closing the vessel early can improve outcomes and be done safely.
This study tests a personalized way to give ibuprofen to very premature babies with a heart condition called PDA. It aims to see if adjusting the dose can help close the heart opening more safely.
This Phase 2 study tests whether giving ibuprofen together with acetaminophen improves outcomes for an important heart connection (PDA) in extremely premature infants. It compares how this medicine approach affects the baby’s heart-related measurements and short-term progress.
This trial measures a substance called prostaglandin E2 (PGE2) in preterm babies to see if it can predict whether a heart blood vessel (ductus arteriosus) will close on its own or need treatment. This could help doctors decide when to use medication to close the vessel.
This trial tests a special stent for babies with a heart defect that needs a temporary blood vessel to stay open. The stent is placed to help blood flow to the lungs until the baby can have a more permanent surgery.
Hear when a new Hemodynamically Significant Patent Ductus Arteriosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.